5-alpha-reductase inhibitor treats symptomatic BPH
GlaxoSmithKline features dutasteride (Avodart), 0.5 mg, an FDA-approved5-alpha-reductase inhibitor for patients with BPH. Initially approved forthe treatment of BPH, the drug is now also indicated for the treatment ofsymptomatic BPH in men with an enlarged prostate to improve urinary symptomsand reduce the risk of urinary retention and the need for BPH-related surgery.
